SCHEMBL2761996

SCHEMBL2761996

Cc1cc2oc(=O)cc(O)c2cc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.61
KDM4E B2RXH2 7/20 0.61
MCL1 Q07820 5/20 0.61
HPGD P15428 4/20 0.61
HSD17B10 Q99714 4/20 0.61
AKR1B1 P15121 2/20 0.61
CYP3A4 P08684 2/20 0.61
THRB P10828 1/20 0.61
KMT2A Q03164 5/20 0.56
CA9 Q16790 4/20 0.53
CA12 O43570 3/20 0.53
CA1 P00915 2/20 0.53
CASP1 P29466 3/20 0.53
CASP7 P55210 3/20 0.53
PIM1 P11309 2/20 0.53
GLA P06280 2/20 0.53
GAA P10253 2/20 0.53
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL7080062 0.98 ALDH1A1 (0.59) ALDH1A1KDM4EMCL1HPGDHSD17B10
Water SCHEMBL7080061 0.98 ALDH1A1 (0.59) ALDH1A1KDM4EMCL1HPGDHSD17B10
SCHEMBL3075970 0.85 MCL1 (0.66) ALDH1A1KDM4EMCL1HPGDHSD17B10
SCHEMBL11856243 0.84 MCL1 (0.67) ALDH1A1KDM4EMCL1HPGDHSD17B10
SCHEMBL11847197 0.84 MCL1 (0.62) ALDH1A1KDM4EMCL1HPGDHSD17B10
SCHEMBL11845819 0.83 KDM4E (0.51) ALDH1A1KDM4EMCL1HPGDHSD17B10
SCHEMBL6365673 0.81 MCL1 (0.68) ALDH1A1KDM4EMCL1HPGDHSD17B10
4,6,7-Trimethyl-2H-Chromen-2-One SCHEMBL19049403 0.81 KDM4E (0.68) ALDH1A1KDM4EMCL1HPGDHSD17B10
SCHEMBL11852445 0.79 KDM4E (0.55) ALDH1A1KDM4EMCL1HPGDHSD17B10
SCHEMBL24865598 0.78 ALDH1A1 (0.82) ALDH1A1KDM4EMCL1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104387405-B Method for synthesizing furo [3,2-c ] coumarin derivative 长沙理工大学 2016-06-15 CN claimed
CN-116256450-A Method for distinguishing acerola cherry fruit powder from acerola cherry juice powder and screening method of characteristic markers of acerola cherry fruit powder 中国农业科学院农业质量标准与检测技术研究所 2023-06-13 CN disclosed
CN-104387405-B Method for synthesizing furo [3,2-c ] coumarin derivative 长沙理工大学 2016-06-15 CN disclosed
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 WO disclosed
US-7538233-B2 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2009-05-26 US disclosed
US-20080153872-A1 Bis-(Coumarin) Compounds With Anti-Inflammatory Activity PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2008-06-26 US disclosed
US-20080153872-A1 Bis-(Coumarin) Compounds With Anti-Inflammatory Activity PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2008-06-26 US disclosed
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
WO-2005010006-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed
EP-0298921-B1 1,2-BENZISOXAZOLES AND 1,2-BENZISOTHIAZOLES CIBA-GEIGY AG (CH) 1992-12-23 EP disclosed
US-4957931-A ANTICONVULSANTS, TREATMENT OF EPILEPSY CIBA-GEIGY CORPORATION (US) 1990-09-18 US disclosed
US-4859691-A Certain 1,2-benzisoxazole derivatives CIBA-GEIGY CORPORATION (US) 1989-08-22 US disclosed
EP-0298921-A1 1,2-Benzisoxazoles and 1,2-benzisothiazoles CIBA-GEIGY AG (CH) 1989-01-11 EP disclosed
US-4288450-A ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1981-09-08 US disclosed
US-4216155-A 3-GLYCOLOYLAMINO-4-OXO-4H-1-BENZOPYRAN; ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1980-08-05 US disclosed
EP-0000488-A1 3-Oxaloamino-4-oxo-4H-1-benzopyrane compounds, process for their preparation and their pharmaceutical use CIBA-GEIGY AG (CH) 1979-02-07 EP disclosed
US-4097475-A FOR POLYESTERS AND BLENDS WITH CELLULOSE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-06-27 US disclosed
US-3974289-A Coumarin derivatives for the treatment of allergies BEECHAM GROUP LIMITED (EN) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153872-A1 Bis-(Coumarin) Compounds With Anti-Inflammatory Activity NOD1, NOD2, CASP1 ALDH1A1 2298/4885KDM4E 4482/4885MCL1 2686/4885
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 ALDH1A1 202/4885KDM4E 550/4885MCL1 2135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.